nifedipine has been researched along with Pancreatitis in 6 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Pancreatitis: INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study failed to demonstrate a significant effect of nifedipine in the prevention of post-ERCP pancreatitis." | 9.10 | Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. ( Amaris, J; Bocquentin, M; Buffet, C; Choury, AD; Ducot, B; Fritsch, J; Pelletier, G; Prat, F, 2002) |
| "The aim of this paper was to evaluate the influence of nifedipine (calcium channel blocker) and Bay-K-8644 (calcium channel agonist) on cerulein acute pancreatitis (AP) in rats." | 7.71 | The influence of nifedipine (calcium channel blocker) and Bay-K-8644 (calcium channel agonist) on the development of experimental acute pancreatitis. ( Celiński, K; Cichoz-Lach, H; Czerny, K; Kleinrok, Z; Słomka, M; Wargocki, J, 2001) |
| "This study failed to demonstrate a significant effect of nifedipine in the prevention of post-ERCP pancreatitis." | 5.10 | Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study. ( Amaris, J; Bocquentin, M; Buffet, C; Choury, AD; Ducot, B; Fritsch, J; Pelletier, G; Prat, F, 2002) |
| "The aim of this paper was to evaluate the influence of nifedipine (calcium channel blocker) and Bay-K-8644 (calcium channel agonist) on cerulein acute pancreatitis (AP) in rats." | 3.71 | The influence of nifedipine (calcium channel blocker) and Bay-K-8644 (calcium channel agonist) on the development of experimental acute pancreatitis. ( Celiński, K; Cichoz-Lach, H; Czerny, K; Kleinrok, Z; Słomka, M; Wargocki, J, 2001) |
| "Nifedipine was used as the antagonist of MCP-1." | 1.38 | Experimental pancreatitis results in increased blood-brain barrier permeability in rats: a potential role of MCP-1. ( Ding, Z; Hou, XH; Lin, R; Liu, J, 2012) |
| "In all patients with acute pancreatitis, the diagnosis of malignant hypertension should be considered." | 1.28 | Malignant hypertension presenting as acute pancreatitis. ( Mathur, R; Warren, JP, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leung, WD | 1 |
| Sherman, S | 1 |
| Ding, Z | 1 |
| Liu, J | 1 |
| Lin, R | 1 |
| Hou, XH | 1 |
| Prat, F | 1 |
| Amaris, J | 1 |
| Ducot, B | 1 |
| Bocquentin, M | 1 |
| Fritsch, J | 1 |
| Choury, AD | 1 |
| Pelletier, G | 1 |
| Buffet, C | 1 |
| Sand, J | 1 |
| Nordback, I | 1 |
| Słomka, M | 1 |
| Celiński, K | 1 |
| Wargocki, J | 1 |
| Kleinrok, Z | 1 |
| Czerny, K | 1 |
| Cichoz-Lach, H | 1 |
| Mathur, R | 1 |
| Warren, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00121901] | Phase 3 | 1,600 participants (Anticipated) | Interventional | 2004-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for nifedipine and Pancreatitis
| Article | Year |
|---|---|
Endoscopic approach to the patient with motility disorders of the bile duct and sphincter of Oddi.
Topics: Bile Ducts; Botulinum Toxins, Type A; Cholangiopancreatography, Endoscopic Retrograde; Dilatation; H | 2013 |
2 trials available for nifedipine and Pancreatitis
| Article | Year |
|---|---|
Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Calcium Channel Blockers; Cholangiopancreatography, E | 2002 |
Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography.
Topics: Abdominal Pain; Acute Disease; Biliary Tract Diseases; Cholangiopancreatography, Endoscopic Retrogra | 1993 |
3 other studies available for nifedipine and Pancreatitis
| Article | Year |
|---|---|
Experimental pancreatitis results in increased blood-brain barrier permeability in rats: a potential role of MCP-1.
Topics: Acute Disease; Animals; Blood-Brain Barrier; Calcium Channel Blockers; Chemokine CCL2; Evans Blue; M | 2012 |
The influence of nifedipine (calcium channel blocker) and Bay-K-8644 (calcium channel agonist) on the development of experimental acute pancreatitis.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2001 |
Malignant hypertension presenting as acute pancreatitis.
Topics: Acute Disease; Adult; Alcohol Drinking; Humans; Hypertension, Malignant; Male; Nifedipine; Pancreati | 1989 |